Adipose-Derived Stem Cells Improved Left Ventricle Wall Thickness and Capillary Density in Pigs Following Myocardial Infarction in Pre-Clinical Study
Just Parking.
biz.yahoo.com
Best of Luck,
SS
>>>>>
Adipose-Derived Stem Cells Improved Left Ventricle Wall Thickness and Capillary Density in Pigs Following Myocardial Infarction in Pre-Clinical Study
Tuesday March 14, 9:30 am ET
Results Presented at 55th Annual Meeting of the American College of Cardiology
SAN DIEGO--(BUSINESS WIRE)--March 14, 2006--Cytori Therapeutics, Inc. (NASDAQ:CYTX - News; Frankfurt:XMPA - News) announced today that adipose-derived stem cells improved left ventricle wall thickness and capillary density following myocardial infarction in a randomized, placebo-controlled preclinical study. The study, sponsored by Cytori Therapeutics, was presented at the 55th annual meeting of the American College of Cardiology (ACC) (Abstract 829-3).
ADVERTISEMENT
The study, conducted at Tulane University, involved administering fresh (uncultured) adipose-derived stem cells or placebo control intra-coronary to 17 pigs after severe myocardial infarctions. All animals received standard of care therapy. The only difference is that one group additionally received their own fresh adipose-derived stem cells. After an eight-week follow-up period, left ventricle wall thickness and capillary density were measured.
The heart wall thickness in the infarct area was greater in the adipose-derived stem cell group than in the placebo group (5.9 mm vs. 3.6 mm), and a similar result was observed in the areas between undamaged and infarcted heart tissue (border regions of the heart -- 11.2 mm vs. 8.6 mm). "This is significant as typically, heart attacks, even with standard of care, may result in a thinning heart wall in the area of damage which may lead to subsequent heart failure," said Alex Milstein, MD, VP of Clinical Development at Cytori Therapeutics.
Capillary density, a measurement of blood supply, was also significantly increased in the border zones of the adipose-derived stem cell treated group compared to the control group. As expected, the healthy, undamaged myocardium showed no significant differences in the wall thickness or capillary density. "These results highlight one of the putative mechanisms of action by which fresh, uncultured adipose stem cells contribute to the repair of damaged cardiac muscle, specifically the angiogenic effects," Milstein said.
"We feel that these results help explain the positive impact of stem cell transplants for heart patients, demonstrating that they do, in fact, work to thicken the heart wall," said Eckhard Alt, MD, of Tulane University. "We believe that stem cells from adipose tissue may be a valuable, novel alternative source for helping support cardiac regeneration after a heart attack."
These results are consistent with previously published functional improvements in multiple pre-clinical studies of adipose-derived stem cells and warrant further investigation of this treatment modality in human trials.
About Cytori Therapeutics
Cytori Therapeutics, Inc. (NASDAQ:CYTX - News; Frankfurt:XMPA - News) is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution(TM) System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events and trends which may affect Cytori Therapeutics' future operating results and financial position. Such statements are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially. Some of these risks and uncertainties are described (under the heading "Risk Factors") in Cytori Therapeutics' Form 10-K annual report for the year ended December 31, 2004 and subsequent SEC filings, which are available through the Company's web site. Cytori Therapeutics assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.
Contact:
Cytori Therapeutics, Inc.
Tom Baker, 858-875-5258 (Investors)
tbaker@cytoritx.com
or
Porter Novelli Life Sciences
Amy Beltran, Ph.D., 858-527-3489 (Media)
abeltran@pnlifesciences.com
--------------------------------------------------------------------------------
Source: Cytori Therapeutics, Inc. |
